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Acetylation of lysine residues is a post-translational modification with broad
relevance to cellular signalling and disease biology. Enzymes that ‘write’
(histone acetyltransferases, HATs) and ‘erase’ (histone deacetylases, HDACs)
acetylation sites are an area of extensive research in current drug
development, but very few potent inhibitors that modulate the ‘reading
process’ mediated by acetyl lysines have been described. The principal
readers of ε-N-acetyl lysine (Kac) marks are bromodomains (BRDs), which are
a diverse family of evolutionary conserved protein-interaction modules. The
conserved BRD fold contains a deep, largely hydrophobic acetyl lysine binding
site, which represents an attractive pocket for the development of small,
pharmaceutically active molecules. Proteins that contain BRDs have been
implicated in the development of a large variety of diseases. Recently, two
highly potent and selective inhibitors that target BRDs of the BET
(bromodomains and extra-terminal) family provided compelling data
supporting targeting of these BRDs in inflammation and in an aggressive type
of squamous cell carcinoma. It is likely that BRDs will emerge alongside HATs
and HDACs as interesting targets for drug development for the large number
of diseases that are caused by aberrant acetylation of lysine residues.
Lysine acetylation is similar to protein
phosphorylation in its prevalence as a post-
translational modification and also has a large
effect on the physicochemical property of the
modified residue. The addition of an acetyl
moiety to the side-chain nitrogen of lysine leads
to neutralisation of charge, which can
significantly influence protein conformation and
protein–protein interactions, thus resulting in
the modulation of enzyme activities and protein
assembly (Ref. 1). The central role of ε-N-
acetylation of lysine residues (Kac) is reflected by
the large number of acetylation sites that have
been identified in proteins (Ref. 2). Acetylation
is particularly abundant in large
macromolecular complexes that are present in
the cell nucleus, suggesting a key role of
acetylation in the regulation of chromatin and
transcriptional control. In particular, the
unstructured tails of histones are hotspots of
acetyl lysine modification. Histone acetylation
levels have been associated with an open
chromatin architecture and transcriptional
activation, but specific marks have also been
linked to chromatin condensation (e.g. H4K16)
(Refs 3, 4), regulation of metabolism (Ref. 5) and
DNA repair (Ref. 6). Acetylation of transcription
factors can either stimulate or silence gene
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stranscription, and inappropriate acetylation levels
have been associated with aberrant transcription
of disease-promoting genes in cancer and
inflammation, instigating the development of
inhibitors for histone deacetylases (HDACs)
(Ref. 7) and histone acetyltransferases (HATs)
(Ref. 8).
Recruitment of proteins to macromolecular
complexes by acetylated lysine residues is
mediated by bromodomains (BRDs), which are
evolutionarily highly conserved protein-
interaction modules that recognise ε-N-lysine
acetylation motifs (Ref. 9). However, BRDs in
BRD4 have recently been shown to bind
propionylated and butyrylated lysine residues
(Ref. 10). BRDs are named after the Drosophila
gene brahma where the BRD sequence motif was
first reported (Refs 11, 12). Since then, BRDs
have been identified in a number of nuclear
proteins such as HATs (Ref. 13), ATP-dependent
chromatin-remodelling complexes (Ref. 14),
methyltransferases (Refs 15, 16) and
transcriptional coactivators (Refs 17, 18, 19)
(Table 1).
Role of BRD proteins in chromatin biology
BRDs have an important role in the targeting of
chromatin-modifying enzymes to specific sites.
Often they act with other protein-interaction
modules to guarantee a high level of targeting
specificity for these essential enzymes. For
example, the methyltransferase ASH1L contains
a combination of one BRD and one plant
homology domain (PHD), as well as a bromo-
adjacent homology domain (BAH) (Ref. 20).
ASH1L is a member of the trithorax group of
transcriptional activators. In Drosophila, ASH1L
activates ultrabithorax expression, and
mammalian homologues have been associated
with actively transcribed genes. Another
example of a multidomain methyltransferase
containing a BRD is the mixed lineage leukaemia
(MLL) gene product (Ref. 21), which is an
essential gene and acts as a key regulator of the
expression of many genes. MLL is required for
proper segment identity in mammals, it displays
haplo-insufficiency and regulates self-renewal of
haematopoietic stem cells by controlling HOX
(homeobox) gene expression (Refs 22, 23, 24).
In addition, the HATs CREBBP and EP300
contain several protein-interaction modules,
including one BRD, and zinc finger and KIX
domains (Ref. 25). Both proteins share a high
degree of sequence similarity and act as
transcriptional coactivators that control a large
variety of biological processes, including cell
growth, genomic stability, development,
neuronal plasticity and memory formation, as
well as energy homeostasis (Ref. 26). CREBBP is
a coactivator of the cAMP response element-
binding CREB transcription factor. The
fundamental role of CREBBP is reflected by the
severe phenotype of homozygous knockout
mice, which die in utero with signs of defective
blood vessel formation in the central nervous
system, developmental retardation, and delays
in both primitive and definitive haematopoiesis
(Ref. 27). Similarly, homozygous deletion of
Ep300 results in mice that die between days 9
and 11.5 of gestation as a result of defects in
neurulation, cell proliferation and heart
development (Ref. 28). Two additional HAT-
containing BRDs have been reported and these
interact with EP300 and CREBBP: PCAF [also
known as K(lysine) acetyltransferase 2B
(KAT2B)] and the related GCN5. Both proteins
acetylate histones and transcription factors, and
act as transcriptional coactivators. Gcn5-
knockout mice die during embryogenesis
because of severe growth retardation, failure in
the development of dorsal mesoderm lineages
and anterior neural tube closure (Refs 29, 30). By
contrast, homozygous deletion of the closely
related Pcaf gene does not show gross
abnormalities, but leads to short-term memory
deficits and an exaggerated response to acute
stress and conditioned fear, associated with
increased plasma corticosterone levels (Ref. 31).
Recent data identified evolutionarily conserved
AAA ATPase ANCCA (AAA nuclear coregulator
cancer-associated protein)/ATAD2 as a protein
required for recruitment of transcription factors
of the E2F family to their target sites, and as a
transcriptional coregulator of Myc, oestrogen
and androgen receptors (ARs). ATAD2
associates through its BRD with histone H3
acetylated at Lys14 during late mitosis,
regulating the expression of genes required for
cell cycle progression (Refs 32, 33, 34).
Dual BRD proteins of the BET (bromodomain
and extra-terminal) familyalso have a pivotal role
regulating the transcription of growth-promoting
genes and cell cycle regulators. The BET family is
represented by four members in humans (BRD2,
BRD3, BRD4 and the testis-specific isoform
BRDT), with each containing two N-terminal
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sTable 1. Bromodomain-containing proteins and their functions
Protein Name Function BRDs
ASH1L Absent, small or homeotic-like Methyltransferase 1
ATAD2A/B AAA domain-containing protein 2 ATPase, coactivator 1
BAZ1A/B BRD adjacent to zinc finger domain
protein 1A
Chromatin assembly and
remodelling
1
BAZ2A/B BRD adjacent to zinc finger domain
protein 2A/B
Unknown 1
BRD1 BRD-containing 1 Transcription factor 1
BRD2 BRD-containing 2 Transcription factor 2
BRD3 BRD-containing 3 Transcription factor 2
BRD4 BRD-containing 4 Transcription factor 2
BRDT BRD-containing protein testis specific Transcription factor 2
BRD7 BRD-containing 7 Transcriptional repressor 1
BRD8A/B BRD-containing 8A/B TRRAP/TIP60 complex 2
BRD9 BRD-containing 9 Unknown 1
BRPF1A/B Peregrin MOZ complex subunit 1
BRPF3A BRD and PHD-finger-containing
protein 3
Unknown 1
BRWD3 BRD and WD-repeat-containing
protein 3
JAK/STATsignalling 2
CECR2 Cat eye syndrome critical region 2 Chromatin remodelling 1
CREBBP CREB-binding protein HAT 1
EP300 HAT p300 HAT 1
FALZ Fetal Alzheimer antigene Chromatin remodelling 1
GCN5L2 General control of amino acid synthesis
protein 5-like 2
HAT 1
MLL Mixed lineage leukaemia Histonemethyltransferase 1
PB1 Polybromo SWI/SNF PBAF subunit 6
PCAF P300/CBP-associated factor HAT 1
PHIP PH-interacting protein Insulin signalling 2
PRKCBP1 Protein kinase C-binding protein 1 Transcriptional regulator 1
SMARCA2A/B SWI/SNF-related, matrix-associated,
actin-dependent regulator of chromatin
SWI/SNF ATPase 1
SMARCA4 SWI/SNF-related, matrix-associated,
actin-dependent regulator of chromatin
SWI/SNF ATPase 1
SP100/SP110/
SP140
Nuclear body protein Transcriptional regulator
TAF1/TAF1L Transcription initiation TFIID-associated
factor
Transcription initiation 2
TRIM24/TRIM28/
TRIM33/TRIM66
Transcription intermediary factor Transcriptional silencer 1
WDR9 BRD and WD-repeat-containing
protein 1
Chromatin remodelling 2
ZMYND11 Zinc finger MYND-domain-containing
protein 11
Corepressor 1
BRD, bromodomain; HAT, histone acetyltransferase; MOZ, monocytic leukaemia zinc finger protein; PHD, plant
homology domain; SNF, sucrose nonfermenting.
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transcriptional elongation by recruiting the
positive transcription elongation factor complex
(P-TEFb). The P-TEFb core complex is composed
of cyclin-dependent kinase-9 (CDK9) and its
activator cyclin T. CDK9 phosphorylates the
RNA polymerase II (RNAPII) C-terminal
domain, a region that contains 52 heptad
repeats. RNAPII undergoes sequential
phosphorylation at Ser5 during promoter
clearance and at Ser2 by P-TEFb at the start of
elongation. It has been shown that BRD4
couples P-TEFb to acetylated chromatin through
its BRDs. Interestingly, in contrast to other BRD-
containing proteins and transcription factors,
BET proteins remain associated with condensed
and hypoacetylated mitotic chromosomes
(Ref. 35), suggesting a role in epigenetic memory
(Refs 36, 37). Homeostasis of BET expression
levels is important for cell cycle control because
both inhibition of BRD4 by microinjected
specific antibodies and overexpression of BRD4
lead to cell cycle arrest in the G2M and G1S
phases, respectively (Refs 38, 39), and genetic
knockdown of BRD4 in cultured human cells
significantly reduces cell growth (Ref. 40). BRD2
associates with the E2F transcription factors and
with the SWI/SNF (switch mating type/sucrose
nonfermenting) complex to regulate the
expression of diverse genes (Ref. 41) such as
cyclin D1 (CCND1) (Ref. 42). BRD2 can function
as a transcriptional coactivator or corepressor in
a promoter-specific or tissue-specific manner.
Deletion of either BRD2 or BRD4 in mice is
lethal, and Brd4
+/– mice also show severe
developmental defects (Refs 43, 44, 45).
Mutagenesis of the Brd2 promoter region
resulted in mice that expressed reduced levels of
BRD2 without causing gross developmental
abnormalities. However, these mice are
extremely obese without developing glucose
intolerance (Ref. 46). The testis-specific BET
family member BRDT is essential for normal
spermatogenesis, and specific deletion of the
first BRD in mice results in abnormal spermatids
and sterility (Ref. 47). In agreement with studies
in mice, altered histone modifications have been
observed in the BRDT promoter region of
subfertile patients (Ref. 48), and genome-wide
association studies linked polymorphism in
BRDT to sterility in European men (Ref. 49).
TandemBRDsarealsopresentinTAF1[RNAPII,
TATA box binding protein (TBP)-associated factor,
250 kDa formerly called TAFII250], the largest
subunit of the general transcription factor TFIID.
TAF1 binds to the core promoter sequence
encompassing the transcriptional start site, and
also interacts with other transcriptional
regulators, thereby modulating the rate of
transcription initiation (Ref. 50). It acts as a
general transcriptional activator and as such
regulates a variety of essential biological
processes, including myogenesis, DNA-damage
response, the cell cycle and apoptosis (Refs 51,
52, 53, 54). The C-terminal tandem BRDs
have been shown to specifically recognise the
diacetylated histone H4 tail at K5/K12 or K8/
K16, as well as diacetylated P53 at K373/K382
at the p21 promoter (Refs 55, 56). TAF1L is a
testis-specific homologue of TAF1. TAF1L is
X-linked and might act as a functional
substitute for TAF1 during male meiosis, when
sex chromosomes are transcriptionally silenced.
Similarly to TAF1, TAF1L can bind to the TATA-
binding protein (TBP) and can functionally
substitute for TAF1 in a temperature-sensitive
hamster cell line (Ref. 57).
The WD repeat proteins BRWD1 (WDR9) and
BRWD3 also contain tandem BRDs. Members of
this family are involved in a variety of cellular
processes, including cell cycle progression,
signal transduction, apoptosis and gene
regulation (Refs 58, 59). Mutations in mice
revealed a role for BRWD1 in spermiogenesis
and the oocyte–embryo transition (Ref. 60).
Despite the specific phenotype in germ-cell
maturation, BRWD1 is widely expressed, and its
expression levels are dynamic during mouse
development. It associates with the SWI/SNF
complex component and functions as a
transcriptional regulator involved in chromatin
remodelling (Ref. 61). Little is known about the
biological function of BRWD3. However, in
Drosophila, BRWD3 function has been genetically
linked to the JAK–STAT pathway (Ref. 62).
Single BRD modules are present in some
members of the tripartite motif (TRIM) family of
transcriptional regulators (Ref. 63). TRIM
proteins are characterised by the presence of a
RING finger, one or two zinc-binding motifs
named B-boxes, and an associated coiled-coil
region (Ref. 64). TRIM24 (Tif1α), for instance,
contains an N-terminal TRIM domain, a nuclear
receptor (LxxLL) interaction motif and a
C-terminal PHD-BRD (Ref. 65). TRIM24
associates with chromatin (Ref. 66) and mediates
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retinoic acid receptor (RAR), and has been
shown to interact with other nuclear receptors
such as thyroid, vitamin D3 and oestrogen
receptors (Ref. 67). TRIM28 (TIF1β)i sa
corepressor for Krüppel-associated box-domain-
containing zinc finger proteins (Ref. 68), which
have a crucial role in early embryogenesis.
TRIM28 associates with heterochromatin-
associated factors HP1α, HP1β and HP1γ to
promote the silencing of euchromatic genes
(Ref. 69), and recruitment of TRIM28 to
centromeres is required for induction of the
parietal and visceral endoderm differentiation
pathways (Refs 70, 71, 72). Interestingly, the
PHD domain of the TRIM28 corepressor
functions as an intramolecular E3 ligase, leading
to sumoylation of the adjacent BRD.
Sumoylation is required for TRIM28-mediated
gene silencing, suggesting that the tightly linked
PHD-BRD module functions as an
intramolecular ubiquitin-like modifier (SUMO)
E3 ligase (Refs 73, 74).
TRIM33 (Tif1γ) is a ubiquitin ligase that targets
SMAD4 (Ref. 75). Formation of transcription
regulatory complexes of SMAD4 with receptor-
phosphorylated SMAD2 and SMAD3 is a
key event in canonical TGFβ signalling.
Consequently, depletion of TRIM33 in human
cell lines inhibits SMAD4-dependent cell
proliferation by competing with SMAD4 for
selective binding to receptor-phosphorylated
SMAD2 and SMAD3 (Ref. 76). Mice deficient in
Trim33 die in utero, demonstrating that TRIM33
has an important role in development (Ref. 77).
The relatively poorly studied TRIM66 (Tif1δ)i s
mainly expressed in testis and, similarly to
TRIM24/33, associates with heterochromatin-
associated factors (HPs) but not with nuclear
receptors, and functions as a transcriptional
silencer (Ref. 78).
The TRIM family member PML (promyelocytic
leukaemia protein TRIM19) has no BRD itself but
associates with SP proteins, a family of three
proteins in humans (SP100, SP110 and SP140)
that all contain a PHD-BRD tandem module
N-terminally flanked by a SAND DNA-binding
domain. The complex of PML and SP100 is
found in nuclear bodies, which are nuclear
structures that have been associated with the
pathogenesis of acute promyelocytic leukaemia
(Ref. 79). Nuclear bodies are implicated in the
regulation of many cellular functions, including
chromatin organisation (Ref. 80), DNA repair
and genome stability (Refs 81, 82), as well as
regulation of transcription (Refs 83, 84, 85). In
addition, the nuclear body is a target of
autoantibodies in patients with primary biliary
cirrhosis (Ref. 86) and is involved in viral
response (Ref. 87). However, little is known
about the precise mechanisms whereby nuclear
body proteins exert their functions.
BRDs have an essential role in the assemblyand
correct targeting of SWI/SNF complexes, which
are particularly rich in BRD interaction modules.
SWI/SNF complexes, also called Brahma-
associated factors (BAFs), remodel chromatin
structure, contributing to either transcriptional
activation or repression of target genes,
depending on the composition of the various
complexes. The components of SWI/SNF
complexes were originally identified in screens
for mutants that result in defects in mating-type
switching in yeast or that were unable to grow
on sucrose (Refs 88, 89, 90). Microarray studies
later showed that SWI/SNF functions as a
transcriptional regulator that affects about 5% of
all genes in yeast (Ref. 91). Mammalian SWI/
SNF complexes have a key role in cell
differentiation and proliferation, and represent
an essential component of the embryonic stem
cell core pluripotency transcriptional network
(Refs 92, 93). All SWI/SNF complexes contain a
core subunit, which alters chromatin structure in
an ATP-dependent manner, resulting in an open
and accessible conformation with increased
affinity for transcription factors (Ref. 94). In
humans, two related SWI/SNF ATPase
components are expressed. These two proteins
are mutually exclusive in SWI/SNF complexes
and have been named after the Drosophila
homologue Brahma as BRG1 (Brahma-related
gene-1, SMARCA4) and the related protein
BRM (SMARCA2). BRG1 and BRM contain a
C-terminal BRD that has been implicated in the
recognition of acetylated lysines within histone
H3 and H4 tails (Ref. 95). Several SWI/SNF
complexes have been shown to mediate critical
interactions between a number of hormone and
other nuclear receptors (Refs 96, 97, 98, 99). In
addition, BRG1 has been shown to associate
with Rb proteins, inducing cell cycle arrest and
transcriptional repression in an HDAC-
dependent manner. BRG1/HDAC-containing
complexes have been shown to repress
expression of genes involved in cell cycle
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sregulation (Refs 100, 101). The chromatin-
remodelling activity of BRG1 has also been
shown to be important for traversal of the
nucleosome by RNAPII (Ref. 102). The SWI/
SNF complex PBAF (polybromo-associated
BRG1-associated factor) is characterised by the
presence of the polybromo protein (PB1) (also
called BAF180) (Refs 103, 104). PB1 is required
for ligand-dependent transactivation by nuclear
hormone receptors and contains six BRDs, two
bromo-associated domains (BAH) and a
homeobox DNA-binding domain. PBAF
complexes, but not BAF, activate vitamin-D-
receptor-dependent transcription in response to
vitamin D, and mice lacking Pb1 have defects in
heart development (Ref. 105) because of
impaired epithelial-to-mesenchymal transition
and arrested maturation of the epicardium as a
result of the downregulation of FGF, TGF and
VEGF signalling (Ref. 106). PB1 also has a role
in cell cycle regulation and is a key regulator of
senescence (Ref. 107).
BRDs are present in chromatin-remodelling
complexes of the ISWI (imitation SWI) family
that assemble into at least seven different
complexes containing a central core ATPase of
the two SNF2-like mammalian homologues
SNF2L and SNF2H of yeast ISWI. ISWI
complexes are key regulators of transcription,
heterochromatin replication and chromatin
structure. The ISWI complex NURF (nucleosome
remodelling factor) contains the BRD PHD
finger transcription factor BPTF. BPTF contains a
C-terminal PHD-BRD and was identified as a
highly expressed protein in patients with
Alzheimer disease as fetal Alz-50 reactive clone
1, and in fetal brain in patients with
neurodegenerative diseases (fetal Alzheimer
antigen, FALZ) (Refs 108, 109). The PHD
domain in BPTF associates with trimethylated
histone H3 Lys4, an interaction that is required
for the recruitment of SNF2L1 to promoters
(Ref. 110). The ISWI complex ACF/WCRF (ATP-
utilising chromatin remodelling and assembly
factor/Williams syndrome transcription factor)
contains BAZ1 (also called WCRF or ACF1), a
protein of the BAZ (BRD adjacent zinc finger)
family, which is represented by four related
genes in humans (BAZ1A, BAZ1B, BAZ2A and
BAZ2B), with similar domain organisation,
including a PHD-BRD interaction module.
BAZ1A was first identified in HeLa cell nuclear
extract as a factor associating with SNF2H
forming a complex with ATP-dependent
chromatin-remodelling activity (Ref. 111).
Later, the SNF2H/BAZ1A remodelling activity
was shown to be required for the DNA-
replication machinery to penetrate condensed
chromatin structures. SNF2H/BAZ1A is
particularly enriched in replicating
pericentromeric heterochromatin, and
knockdown of BAZ1A by RNAi impairs
replicationofcondensedchromatin(Refs112,113).
BAZ2A (TIP5, TTF-1-interacting protein 5) is a
key subunit of the NoRC (nucleolar remodelling
complex), which mediates transcriptional
silencing of ribosomal RNA (Ref. 114).
Interestingly, mutation of a tyrosine residue in
the BAZ2A BRD in yeast impairs interaction
with acetylated histones (Ref. 115) and the
mutation Y1775F represses NoRC interaction
with chromatin and RNA polymerase I
transcription (Ref. 116). A table containing all
human BRD proteins identified to date and a
phylogenetic tree of this protein family is shown
in Table 1 and Figure 1a, respectively.
BRD substrates
Given the central role of BRDs in epigenetic gene
regulation, it is surprising that only a few
substrates have been reported and mapped to
specific sites. Reported affinities range from low
micromolar to millimolar KD values, raising
questions regarding the physiological relevance
of described weak in vitro substrate interactions,
as well as which additional factors contribute to
binding specificity (Table 2). BRDs are often
associated with other protein-interaction
modules, a mechanism that is thought to
generate high target selectivity and increased
binding affinity with substrates owing to avidity
that is generated on simultaneous binding of
several interaction domains. This property led to
the suggestion that epigenetic regulation
recognises patterns of post-translational
modifications (words) rather than single
modifications (letters) (Ref. 130). In addition, the
reading process might require combinations of
several modifications for high-affinity
interaction with a single BRD. Recently,
Moriniere and coworkers showed that the testis-
specific BET isoform BRDT requires the presence
of several acetylation sites for high-affinity
binding to histone tails (Ref. 118). Interestingly,
both acetylated lysines interact with the same
binding pocket in BRDT (Fig. 1b). It is also
expert reviews
http://www.expertreviews.org/ in molecular medicine
6
Accession information: doi:10.1017/S1462399411001992; Vol. 13; e29; September 2011
© Cambridge University Press 2011. Re-use permitted under a Creative Commons Licence – by-nc-sa.
B
r
o
m
o
d
o
m
a
i
n
s
a
s
t
h
e
r
a
p
e
u
t
i
c
t
a
r
g
e
t
slikely that other post-translational modifications,
such as phosphorylation and methylation,
influence substrate recognition, providing the
basis for crosstalk of transcription control and
cellular signalling. Similarly, the related BRD
protein BRD3 also requires two adjacent
acetylation sites for tight interaction with the
transcription factor GATA1 (Ref. 131).
BRDs as therapeutic targets in cancer
Many proteinsthat use BRDs for their recruitment
to specific regulatory complexes have been
implicated in the development of cancer. BRD-
containing proteins are usually multicomponent,
and often the reported disease association has
not been directly linked to defects in the BRD
module itself. However, a number of dominant
oncogenic rearrangements and correlation of
overexpression of BRD proteins with patient
survival provide a strong case for targeting
BRDs in cancer.
Genetic rearrangements of BRD-containing
proteins have been linked to the development of
a number of extremely aggressive tumours. A
very aggressive poorly differentiated carcinoma
that originates mainly from midline locations
such as the head, neck or mediastinum is NUT
(nuclear protein in testis) midline carcinoma
(NMC) (Ref. 132). NMCs are genetically
characterised by translocations that involve the
NUT protein with BRD4, BRD3 or an unknown
partner gene. BRD4–NUT rearrangements are
TRIM33B ab
c
TRIM24
TRIM66 TRIM28
BAZ1A
BAZ2A
BRD2(1)
BRD3(1)
BRD4(1)
BRDT(1) BRD2(2)
BRD3(2)
BRD4(2)
BRWD3(1)
BRDT(2)
WDR9(1)
PHIP(1)
PB1A(3)
PB1B(3)
PB1(1)
PB1(2)
PB1(4)
PB1(5)
PB1(6)
ASH1L
ZMYND11
BRD9
BAZ2B
PHIP(2)
WRD9(2)
BRWD3(2)
EP300 MLL
BAZ1B CREBBP
BRD7 BRD8A
BRD8B(1)
BRD8B(2)
ATAD2B
ATAD2A BRPF1A
BRPF1B
BRPF3
BRD1
TAF1(1)
TAF1L(1)
TAF1(2)
TAF1L(2)
PRKCBP1
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SP140
BRD4
H3K14ac
H4K5acK8ac
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N140 N140
K14 K14ac ac
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SP100
SP110A
SP110C
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SMARCA2B
SMARCA4
GCN5L2
PCAF
FALZ
CECR2
TRIM33A
Phylogenetic tree of the human bromodomain family and substrate
recognition of bromodomains
Expert Reviews in Molecular Medicine © 2011 Cambridge University Press
Figure 1. Phylogenetic tree of the human bromodomain family and substrate recognition of
bromodomains. (a) Phylogenetic tree based on sequence alignments of predicted BRDs. For targets with
multiple BRDs, the domains have been numbered starting from the N-terminus and the number is shown in
parentheses. (b) Interaction of mouse BRD4 (Ref. 117) and mouse BRDT (Ref. 118) with monoacetylated
Lys14 in histone H3 and a diacetylated H4 peptide monoacetylated on both Lys5 and Lys8. (c) Surface
representation in similar orientation. See Table 1 for an explanation of protein symbols.
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sTable 2. Bromodomain substrates with known affinity
BRD Sequence Affinty (μM)
a Refs
BRD2 H4K12 2900 (NMR) 119
H4K5/12 140 (SPR) 120
BRD4(1) H3K14 118 ±28 (ITC) 10
H3K14-propyl 337 ±76 (ITC)
H3K23-propyl 380 ±105 (ITC)
H4K5 325 ±72 (ITC) 117
H4K5 810 (NMR) 121
H4K12 650 (NMR)
H4K5/K8 38 ± 3.7 (ITC) 10
BRD4(2) H3K14 327 ±75 (ITC) 10
H3K14-propyl 213 ±15 (ITC)
H3K23-propyl 208 ±16 (ITC)
H4K5 107 ±23 (ITC) 117
H4K5 1000 (NMR) 121
H4K12 1350 (NMR)
H4K5/K8 212 ±32 (ITC) 10
BRDT(1) H2BK12/15 157 ±15 (ITC) 118
H3K9/14/18/23 390 ±36 (ITC)
H4K5/8 21.9 ±1.7 (ITC)
H4K8/12 193 ±22 (ITC)
H4K12/16 117 ±22 (ITC)
H4K5/12 340 ±67 (ITC)
H4K5/8/12/16 28.0 ±6.1 (ITC)
BRDT(2) H3K9/14/18/23 214 ±48 (ITC)
H3K14/18 217 ±28 (ITC)
H3K18/23 176 ±52 (ITC)
H3K9/18 360 ±140 (ITC)
H3K18 251 ±62 (ITC)
BRD7 H3K9 3960 (NMR) 122
H3K14 1190 (NMR)
H4K8 1790 (NMR)
H4K12 3420 (NMR)
H4K16 2560 (NMR)
CREBBP H4K20 218 (NMR) 123
H3K36 122 (NMR)
p53K382 187 (NMR), 155 (FP)
GCN5L2 H4K8 900 (NMR) 124
H4K16 900 (NMR)
PB1 H3
b 1.1 - 34 (FA) 125
PB1(1) H3K4 390 (FP) 126
PB1(2) H3K9 360 (FP)
PB1(4) H3K23 120 (FP)
PCAF H4K8 346 ±54 (NMR) 127
H3K9 1051 (NMR) 123
H3K14 128 (NMR)
H3K36 402 (NMR)
H4K16 365 (NMR)
H4K20 247 (NMR)
TATK50 84 (NMR), 212 (FP)
SMARCA4 H3K9/14 500 (NMR) 128
H3K14 1200 (NMR) 95
H4K8 4000 (NMR)
H4K12 3600 (NMR)
TAF1 (BRD-BRD) H4K16 39 ± 7 (ITC) 55
H4K8/16 5.6 ±0.2 (ITC)
H4K5/12 1.4 ±0.3 (ITC)
H4K5/8/12/16 5.3 ±0.2 (ITC)
TRIM24 (PHD-BRD) H3K9 232 ±33 (ITC) 129
H3K14 229 ±32 (ITC)
H4K16 26 ± 2 (ITC)
H3K23 0.07 ±0.01 (ITC)
aMethod of affinity experiments are in parentheses.
bHistone H3 residues 1-25 with single acetylations on K4, K9, K14, K18 or K23.
Abbreviations: FA, stopped-flow fluorescence anisotropy; FP, fluorescent polarization; ITC, isothermal titration calorimetry; NMR, nuclear
magnetic resonance; SPR, surface plasmon resonance.
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Both BRD4–NUT and BRD3–NUT fusion genes
encode proteins composed of the N-terminal
tandem BRDs and almost the entire NUT gene
(Fig. 2). BRD–NUT blocks cellular differentiation,
and depletion of this oncogene by RNAi results
in squamous differentiation and cell cycle arrest
(Refs 133, 134). BRD4–NUT specifically recruits
CBP/p300, leading to stimulation of CBP/p300
HAT activity, formation of nuclear foci and
inactivation of p53 (Ref. 135). Selective inhibition
of BRD4–NUT by recently developed acetyl
lysine competitive inhibitors results in epithelial
differentiation, tumour shrinkage and survival in
BRD4–NUT xenograft mice (Ref. 136).
Chromosomal translocations of CREBBP with
the MLL protein and the monocytic leukaemia
zinc finger protein (MOZ) have been described
in myeloid and lymphoid acute leukaemia and
myelodysplasia secondary to therapy with
drugs targeting DNA topoisomerase II
(Refs 137, 138) (Fig. 2). CREBBP also contributes
to tumourigenesis of NUP98–HoxA9 and
MOZ–TIF2 fusion proteins by activating
transcription (Refs 139, 140). In addition,
CREBBP mutations have been identified in
relapsed acute lymphoblastic leukaemia
(Ref. 140) and are very common in diffuse large
B-cell lymphoma and follicular lymphoma,
constituting the major pathogenetic mechanism
shared by common forms of B-cell non-
Hodgkin’s lymphoma (Ref. 141). CREBBP and
the related HAT EP300 are also highly expressed
in advanced prostate cancer, and expression
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Figure 2. Domain organisation of bromodomain proteins and translocations in cancer. BRD modules are
shown in green (labelled BRD). Other domain types are labelled directly in the figure and breakpoints are
indicated by arrows. Wild-type domain arrangements are shown in the upper panel. See Table 1 for an
explanation of protein symbols.
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slevels have been linked with cancer patient
survival (Ref. 142).
Overexpression of several BRD proteins has
been reported in cancer and has been linked to
patient survival. For instance, a recent study
showed that ATAD2 is overexpressed in more
than 70% of breast tumours and that higher
protein levels correlate with tumour histological
grades, poor overall survival and disease
recurrence (Ref. 33). Revenko and coworkers
showed that ATAD2 is required for recruitment
of specific E2F transcription factors and for
chromatin assembly of the host cell factor
1–MLL histone methyltransferase complex. As a
result of its association with the MLL
methyltransferase, depletion of ATAD2 results in
a marked decrease of trimethylation of Lys4 in
histone H3, which has been linked to
transcriptional activation. BRD mutations
disable ATAD2 function as an E2F coactivator
and its ability to promote cancer cell
proliferation (Ref. 32). The closely related
protein ATAD2B has recently been shown to be
highly expressed in glioblastoma and
oligodendroglioma, as well as in breast
carcinoma (Ref. 143).
Aberrant expression has also been reported for
TRIM24 in breast cancer, and high expression
levels have been shown to negatively correlate
with survival of breast cancer patients (Ref. 129).
In liver, however, TRIM24 seems to function as
a liver-specific tumour suppressor (Ref. 144).
TRIM24 also interacts with AR and enhances
transcriptional activity of the AR by
dihydrotestosterone in prostate cancer cells
(Ref. 145). These data suggest that TRIM24
function and its role in tumourigenesis might be
highly context dependent.
The testis-specific BET family member BRDT is
frequently overexpressed in non-small-cell lung
cancer (Ref. 146) and several other cancers
(Ref. 147), but the functional consequences of
BRDT overexpression have not been investigated
so far. The role of BRD4 in cancer is better
understood. BRD4 has been shown to be a key
regulator of cell cycle control and transcriptional
elongation of growth-promoting genes. In
particular, the key role of BRD4 in the
recruitment of P-TEFb (CDK9/cyclinT) to
transcriptional start sites provides an alternative
strategy to targeting CDK9, which emerged as a
validated target in chronic lymphocytic
leukaemia (Ref. 148). In breast cancer, however,
BRD4 has been identified as an inherited
susceptibility gene for disease progression and
its expression levels have been associated with
patient survival (Ref. 149). BRD4 and BRD2 also
have a key role for the transmission of tumour
viruses during mitosis by providing a chromatin
anchor to viral episomes. For instance, during
latent viral infection of herpes viruses associated
with development of Kaposi sarcoma, the
transmission of viral genomes to daughter cells
during mitosis is mediated by the episome’s
latency-associated nuclear antigen 1, which is
tethered to chromatin through its interaction
with BRD4 (Ref. 150). Also, papilloma viruses
that have been linked to the development of
cervical cancers and Epstein–Barr viruses
associate with BRD4 in order to anchor their
viral genomes to mitotic chromosomes
(Refs 151, 152).
BRDs as therapeutic targets for the
treatment of inflammation
Transcriptional control of proinflammatory
cytokines is the central mechanism in the
aetiology of inflammatory disease, and given the
success of HDAC inhibitors in this area, it is
likely that selective BRD inhibitors will
modulate these processes. A first example has
been provided by the recent pan-BET inhibitor
iBET, which leads to the disruption of chromatin
complexes responsible for the expression of
inflammatory genes and conferred protection
against lipopolysaccharide-induced endotoxic
shock and bacteria-induced sepsis (Ref. 153).
Three sites of polymorphism in BRD2 have
recently been linked to rheumatoid arthritis
(Ref. 154) and Brd2-hypomorphic mice are
severely obese and have reduced inflammation
in fat tissue (Ref. 46).
The BRD-containing HATs EP300/CREBBP
have been proposed as therapeutic targets in
inflammatory diseases such as lung
inflammation and asthma (Ref. 155). Activation
of proinflammatory genes is intimately linked to
activation of nuclear factor κB (NFκB). The
activated p65 subunit translocates to the
nucleus, where its affinity to its target genes and
transcriptional activity is regulated by
acetylation by EP300/CREBBP. Compounds that
inhibit NFκB acetylation such as the natural
product gallic acid have anti-inflammatory
properties (Refs 156, 157). EP300 and PCAF also
regulate inflammatory responses through their
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sregulation of cyclooxygenase-2 (COX2)
expression. COX2 is a key enzyme of
prostaglandin biosynthesis that is well
established as a major player in inflammatory
response and a clinically successful target for the
development of anti-inflammatory drugs.
Stimulation by bacterial lipopolysaccharides and
other cytokines leads to increased binding of
PCAF and EP300 to the COX2 promoter, and its
activation. Conversely, inhibitors of EP300 have
been shown to reduce COX2 protein levels and
promoter activities (Ref. 158).
The concerted activation of several
proinflammatory genes is regulated by the SWI/
SNF class of ATP-dependent remodelling
complexes, which make the promoters of
inflammatory genes permissive for
transcriptional induction. The presence of the
catalytic ATPase subunit BRG1 at the promoter
of proinflammatory genes such as IL6 has been
shown to be necessary for activation of these
genes, and termination of transcriptional
activation is regulated by proteasomal
degradation of BRG1, ensuring a timely and
adequate immune response (Ref. 159). Although
experimental data are still missing, it is
intriguing to speculate that removal of BRG1
from promoter regions might have an effect on
inflammatory conditions.
BRDs as therapeutic targets for the
treatment of neurological diseases
Increasing evidence points to the fact that
epigenetic targets have a role in the molecular
manifestation of stress and related disorders.
Because BRD inhibitors have only just been
discovered, no study has addressed the role of
BRD inhibition in neurological disorders so far.
However, several studies report important
functions of BRD-containing proteins in several
diseases. TRIM28, for instance, is highly
expressed in the mouse hippocampus and
cerebellum. Inducible deletion of Trim28 in the
forebrain of adult mice resulted in stress-related
behaviour and cognitive impairment of these
mice similar to effects observed in behavioural
disorders such as borderline personality or
bipolar disorder. Chromatin immunoprecipitation
experiments confirmed changes in histone
methylation and acetylation patterns in the
promoter regions of TRIM28 target genes such as
Mkrn3 and Pcdhb6 (Refs 160, 161).
TwootherBRD-containingproteins,SMARCA2
(BRM)andBRD1,havebeenidentifiedingenome-
wideassociationstudiesassusceptibilitygenesfor
schizophrenia and bipolar disorder in several
independent studies, but the molecular
mechanisms are still unclear (Refs 162, 163). In
addition, low levels of SMARCA2 have been
found in the post-mortem prefrontal brains of
schizophrenic patients, and the gene expression
profiles in the diseased brains match those after
downregulation of SMARCA2 in cells and in
SMARCA2-knockout mice, which show impaired
social interaction and prepulse inhibition.
Interestingly, SMARCA2 expression can be
increased in the mouse brain on application of
antipsychotic drugs, providing further evidence
of the potential of this protein as a target for the
treatment of schizophrenia (Refs 164, 165).
Mutations in CREBBP, and less frequently in
EP300, are the genetic background for
Rubinstein–Taybi syndrome (RTS), a rare human
genetic disorder characterised by mental
retardation and physical abnormalities; many
patients with RTS have either breakpoints or
microdeletions in chromosome 16p13.3 where
the CREBBP gene is located, but also
heterozygous point mutations can lead to RTS
(Refs 166, 167, 168). Several of the pathological
features can be mirrored by heterozygous
Crebbp-deficient mice strains (Refs 169, 170, 171).
Although the precise mechanisms underlying
the disease are not yet understood, it is thought
that the HAT activity of CREBBP and reduced
transcriptional activity result in altered synaptic
plasticity, which ultimately influences long-term
memory, leading to mental retardation
(Ref. 172). EP300 also has a role in the aetiology
of amyotrophic lateral sclerosis, Alzheimer
disease and Huntington disease. Huntington
disease is a polyQ disease in which
polyglutamine repeats are added to the
Huntingtin protein, causing its translocation to
the nucleus and formation of aggregates.
CREBBP and PCAF interact directly with
Huntingtin aggregates, resulting in their
depletion (Refs 173, 174). Indeed, HDAC
inhibitors have long been used as mood
stabilisers and are studied for the treatment of
Huntington and Alzheimer diseases (Ref. 175).
Development of BRD inhibitors
BRDs share a conserved fold that comprises a left-
handed bundle of four alpha helices (αZ, αA, αB,
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sαC), linked by highly variable loop regions (ZA and
BC loops), which form the rim of the substrate-
binding pocket and determine substrate
recognition (Refs 55, 127) (Fig. 3a). Despite the
conservation of the overall BRD fold, the surface
and loop regions of BRDs are highly diverse,
suggesting that inhibitors with high specificity can
be designed. Cocrystal structures with peptidic
substrates have demonstrated that the acetyl lysine
is recognised by a central deep hydrophobic cavity,
where it is anchored by a hydrogen bond to an
asparagine residue present in most BRDs
(Ref. 177). Acetylation of lysine residues neutralises
t h ec h a r g eo ft h eε-amino group. As a
consequence, the central cavity of acetyl lysine
binding sites in BRDs is quite hydrophobic and
particularly rich in aromatic residues; it also has
sufficient size to accommodate potent acetyl lysine
competitive ligands. These properties make BRDs
attractive targets for the design of
pharmacologically active molecules that compete
withproteininteractionsmediatedbythesemodules.
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Figure 3. Structural overview of a bromodomain and binding mode of bromodomain inhibitors. (a) Ribbon
diagram of thefirst BRDof BRD4. The mainstructural elements aswellastheacetyl lysinebinding site residues
are labelled. (b) Superimposition of a diacetylated BET substrate peptide and the inhibitor JQ1. Inhibitor and
peptide molecules are shown in stick representation and are coloured according to atom types. (c) Binding
of JQ1 to the bromodomain of BRD4. Conserved water molecules in the active site are highlighted and
hydrogen bonds are shown as dashed lines. (d) Complex of ischemin with CREBBP (Ref. 176).
expert reviews
http://www.expertreviews.org/ in molecular medicine
12
Accession information: doi:10.1017/S1462399411001992; Vol. 13; e29; September 2011
© Cambridge University Press 2011. Re-use permitted under a Creative Commons Licence – by-nc-sa.
B
r
o
m
o
d
o
m
a
i
n
s
a
s
t
h
e
r
a
p
e
u
t
i
c
t
a
r
g
e
t
sPotent and very selective inhibitors have
recently been published for BET BRDs (Refs 136,
153, 178). All inhibitors that have been
published so far are based on a triazolo-
diazepine scaffold that successfully mimics
interactions observed in BET peptide complexes
(Fig. 3b). Interestingly, a number of tightly
bound and conserved water molecules remain in
cocrystal structures of BET triazolo-diazepine
complexes, which interact with the inhibitor
through a network of hydrogen bonds (Fig. 3c).
Two BET inhibitors have been studied in two
different disease models, providing compelling
support of BET BRDs as targets in drug
discovery. The inhibitor JQ1 has been studied in
midline carcinoma where inhibition of
BRD4–NUT led to terminal differentiation, cell
cycle arrest and apoptosis of carcinoma cells,
and significant reduction of tumour growth in
patient-cell-line-derived xenograft models
(Ref. 136). The inhibitor iBET led to significant
reduction of the expression of proinflammatory
genes in activated macrophages, and conferred
protection against lipopolysaccharide-induced
endotoxic shock and bacteria-induced sepsis,
supporting inhibition of BET BRDs as a strategy
for the generation of immunomodulatory drugs
(Ref. 153).
Acetyl lysine mimetic inhibitors have also been
reported in the case of CREBBP, competing for its
interaction with p53. These inhibitors were
identified by NMR screening using a library of
compounds that consists of one aromatic ring
connected to an −NHCOCH3 group by different
types of linkers (Ref. 179). The same laboratory
also reported a series of cyclic peptides with
improved binding affinities over natural
substrates (Ref. 179) and azobenzene-based
inhibitors such as 4-hydroxyphenylazo-
benzenesulfonic acid (MS456) and ischemin.
Ischemin binds to the BRDs of CREBBP with a
dissociation constant (KD)o f1 9μM and shows
at least fivefold selectivity over other human
BRDs. The binding mode of ischemin in
CREBBP is shown in Figure 3d. In cellular
assays ischemin alters post-translational
modifications of p53 and histones, inhibits p53
interaction with CBP and transcriptional activity
in cells, and prevents apoptosis in ischaemic
cardiomyocytes (Ref. 179). Early lead
compounds such as N1-aryl-propane-1,3-
diamine have also been identified for PCAF
(Ref. 180). A summary of the chemical structures
of the currently most advanced BRD inhibitors
is shown in Figure 4.
Research in progress and outstanding
research questions
Targeting BRDs for the development of protein-
interaction inhibitors has recently emerged as a
strategy for the design of pharmacologically
active reagents. The relatively weak interaction
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Figure 4. Chemical structures of bromodomain inhibitors. Specificity and dissociation constants are also
indicated.
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sof BRDs with their substrates, the diversity and
physicochemical properties of the acetyl lysine
binding site, and the large number of available
crystal structures will facilitate the rational
design of such inhibitors. However, BRDs
usually constitute only one of the interaction
domains found in BRD-containing proteins, and
whether selective inhibition of the acetyl lysine
interaction alone will result in the desired
phenotype needs to be investigated in future
research projects. The large number of diseases
that have been linked to BRD-containing
proteins and the success of particular HDAC
inhibitors indicate that BRD inhibitors will
find a large number of applications in
pharmaceutical sciences and basic research.
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Websites
Bromodomain structures solved by the Structural Genomics Consortium:
http://www.sgc.ox.ac.uk/structures/BRO.html
Chemical probe resource for epigenetic targets:
http://www.thesgc.org/chemical_probes/epigenetics/
Disease-annotated chromatin epigenetic resource:
http://wodaklab.org/dancer/
The chromatin database:
http://www.chromdb.org/
Human Histone Modification Database (HHMD):
http://bioinfo.hrbmu.edu.cn/hhmd/
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Figure 1. Phylogenetic tree of the human bromodomain family and substrate recognition of bromodomains.
Figure 2. Domain organisation of bromodomain proteins and translocations in cancer.
Figure 3. Structural overview of a bromodomain and binding mode of bromodomain inhibitors.
Figure 4. Chemical structures of bromodomain inhibitors.
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